High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$15.6M
$15,621,068
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
| BBIO |
BridgeBio Pharma, Inc.
|
Director
Other
|
2026-03-04 | $548,582 | M | Form 4 |
|
BBIO
S
BridgeBio Pharma, Inc.
Ellis Andrea
• Director
10b5-1 SellΔOwn -77.7%
2026-03-04
$4,211,302Large
|
||||||
| BBIO |
BridgeBio Pharma, Inc.
|
Director
10b5-1 SellΔOwn -77.7%
|
2026-03-04 | $4,211,302Large | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
Director
Other
|
2026-02-27 | $1,234,700Large | M | Form 4 |
|
BBIO
S
BridgeBio Pharma, Inc.
Valantine Hannah
• Director
10b5-1 SellΔOwn -44.3%
2026-02-27
$1,717,781Largex2
|
||||||
| BBIO |
BridgeBio Pharma, Inc.
|
Director
10b5-1 SellΔOwn -44.3%
|
2026-02-27 | $1,717,781Largex2 | S | Form 4 |
|
BBIO
S
BridgeBio Pharma, Inc.
Apuli Maricel
• Officer • Chief Accounting Officer
10b5-1 Sell
2026-02-26
$132,000
|
||||||
| BBIO |
BridgeBio Pharma, Inc.
|
Officer • Chief Accounting Officer
10b5-1 Sell
|
2026-02-26 | $132,000 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2026-02-19 | $2,002,717Largex3 | S | Form 4 |
|
BBIO
S
BridgeBio Pharma, Inc.
Apuli Maricel
• Officer • Chief Accounting Officer
10b5-1 Sell
2026-02-17
$37,898
|
||||||
| BBIO |
BridgeBio Pharma, Inc.
|
Officer • Chief Accounting Officer
10b5-1 Sell
|
2026-02-17 | $37,898 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
Director
Other
|
2026-02-17 | $167,500 | M | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
Director
10b5-1 Sell
|
2026-02-17 | $754,557x3 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CFO
10b5-1 Sell
|
2026-02-17 | $1,016,147Largex2 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2026-02-11 | $2,871,087Largex8 | S | Form 4 |
| BBIO |
BridgeBio Pharma, Inc.
|
CEO
10b5-1 Sell
|
2026-02-10 | $2,877,580Largex4 | S | Form 4 |